Amphion Innovations (AMP)


LSE:AMP: Results of AGM and Directorate Change

Amphion Innovations

29 Jul 2016 07:00:13

Amphion Innovations

RNS Number : 6005F
Amphion Innovations PLC
29 July 2016

Amphion Innovations plc

 ("Amphion" or "the Company")

Results of AGM and Directorate Change

London and New York, 29 July 2016 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, today announces that all resolutions were passed at the Annual General Meeting, which was held on Wednesday 27 July 2016. 

Included in the resolutions were the appointments to the Board of Mr. Richard Mansell-Jones as Director and Chairman and Mr. Paul Kennedy as Non-executive Director, effective immediately. 

Richard Mansell-Jones is a former Non-executive Chairman of Amphion, and has great experience of public company leadership and governance. Mr. Mansell-Jones was Non-executive Chairman of Brown, Shipley & Co. Limited from 1992 until 2003. From 1988 until 2000 he was Executive Chairman of J. Bibby & Sons PLC (subsequently Barloworld PLC); from 1992 until 2005 he was a Non-executive Director of Standard Bank London Limited (now Standard Bank PLC), where latterly he served as Chairman of the Audit Committee, and from 2001 until 2006 he was Non-executive Chairman of Millfield Group plc. Furthermore, Mr. Mansell-Jones is a Non-Executive Director of a number of charities, including Burlington Magazines Publications Limited and World Monuments Fund Britain Limited.  After reading Literae Humaniores at Worcester College, Oxford, he was articled to Price Waterhouse & Co, becoming a Chartered Accountant, before joining N. M. Rothschild & Sons in 1968.


Paul Kennedy has an extensive career in the pharmaceutical industry, occupying senior management positions with major pharmaceutical companies as well as working and investing as an entrepreneur in smaller biotechnology companies. Mr. Kennedy worked as a Marketing Director for seven years at Abbott France and Boots, both in the UK and France, before joining Novo Nordisk France, where he was President for 15 years. Having left Novo Nordisk in 1994, Mr. Kennedy set up his own pharmaceutical company, Laboratoires Murat, which was purchased by Fuisz Technologies Ltd, a Nasdaq-listed drug delivery company, three years later. Mr. Kennedy then worked as Executive Vice President, Operations for Fuisz Technologies in Paris, adding acquisitions in France, Germany and Italy, before the business was sold to Shire plc in 1999. From 1999 to 2004 he worked as an Independent Consultant in the pharmaceutical industry, and in 2004, Mr. Kennedy became President of International Operations at AIM-listed medical diagnostics company Cozart plc. In 2007, Mr. Kennedy became a controlling shareholder and Director of US listed IVAX Diagnostics, Inc, which was subsequently sold to Transasia Bio-Medicals Ltd, India's largest diagnostics company, in September 2010. Mr. Kennedy is currently a director of Venn Life Sciences Holdings plc and has participated as an investor in several AIM IPOs.


Save as disclosed below, there are no further details required to be disclosed pursuant to schedule 2(g) of the AIM rules.


Richard Mansell Mansell-Jones, age 76, is currently a director of, or during the past five years has been a director of, the following companies:


Current directorships and partner positions

Past directorships held within the last 5 years

British Sporting Arts Trust

Burlington Magazine Foundation

Burlington Magazine Publications Limited (The)

World Monuments Fund Britain Limited



Mr. Mansell-Jones' beneficial interests in the Company amounts to 3,785,530 ordinary shares in the Company ("Ordinary Shares"), representing 1.92% of the Company's issued share capital, £39,677.30 of convertible unsecured promissory notes and 79,354 warrants over Ordinary Shares.


Heim Gallery (London) Limited entered receivership in June 1991 and was dissolved on 12 November 2002, during which time Mr. Mansell-Jones was an appointed director.


Millfield Group plc, where Mr. Mansell-Jones was a director until 25 August 2006, entered into administration on 13 July 2006 before entering into a creditors' voluntary liquidation on 29 May 2007, and was dissolved on 20 June 2012.


Paul Francis Kennedy, age 71, is a director of Venn Life Sciences plc, and currently holds no beneficial interests in the Company.


For further information please contact:


Amphion Innovations
Charlie Morgan
+1 212 210 6224

Yellow Jersey PR

Charles Goodwin / Dominic Barretto
+44 (0)7747 788 221

Panmure Gordon Limited (Nominated Adviser and Corporate Broker)

Freddy Crossley / Duncan Monteith (Corporate Finance)
Charlie Leigh-Pemberton (Corporate Broking)
+44 (0)20 7886 2500


Northland Capital Partners Limited (Joint Corporate Broker) 
Patrick Claridge / David Hignell (Corporate Finance)
John Howes (Corporate Broking)
+44 (0)20 3861 6625 

Plumtree Capital Limited (Financial Adviser)
Stephen Austin
+44 (0)20 7183 2493
+646 568 7502


This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.



About Amphion Innovations plc


Amphion Innovations is a developer of medical, life science and technology businesses.


We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.


On the web: 


This information is provided by RNS
The company news service from the London Stock Exchange